Invitation: Cancer-Associated Thrombosis Roundtable Discussion at the EU | 16 October
You Are Invited to Attend a Roundtable Discussion on Cancer-Associated Thrombosis and the EU Cancer Agenda Event in Recognition of World Thrombosis Day
MEP Juozas Olekas and the European Thrombosis and Haemostasis Alliance (ETHA) are delighted to invite you to a roundtable discussion on Cancer-Associated Thrombosis and the EU Cancer Agenda 2019 – 2024 in recognition of the sixth annual World Thrombosis Day (WTD) campaign.
As a strong risk factor for developing blood clots, research indicates that cancer patients have a four-times higher risk than the general population of developing a clot. Blood clots are a serious complication of cancer with cancer-associated thrombosis as the leading cause of morbidity and mortality in cancer patients.
To address this important topic and to hear from the experts in the fields of cancer and thrombosis, please register to attend below.
- WHEN: Wednesday 16 October 2019 | 13:00 – 15:00
- WHERE: European Parliament, Brussels, Rue Wiertz 60, Room ASP 3H1
- REGISTER: To register, click here. If you do not have an access badge, please arrive at the Esplanade in front of the European Parliament 12.30 in order to be accompanied to the meeting room.
Through Europe’s Beating Cancer Plan envisaged by Commission President-elect von der Leyen, the European Union has made the fight against cancer a top priority. According to the Mission Letter to Health-Commissioner designate Stella Kyriakides, Europe’s Beating Cancer Plan is intended to have actions at every stage of the disease: prevention, diagnosis, treatment, life as a cancer survivor and palliative care.
Stronger EU cooperation is essential to tackle cancer given the significant impact of this disease, especially against wider trends such as rising cancer prevalence and increasing demand for healthcare services due to ageing populations. However, when developing the target areas for Europe’s Beating Cancer Plan, we can’t lose sight of the central goals of improving overall cancer survival rates and concurrently decreasing use of healthcare resources. Improvements at every stage of the disease, from early intervention to better treatment and outcomes, can best be safeguarded by addressing risk factors which affect mortality from all cancers, like cancer-associated thrombosis.